Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
efficacy
renal impairment
safety
sofosbuvir
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
10
06
2019
revised:
15
09
2019
accepted:
28
10
2019
pubmed:
21
12
2019
medline:
22
6
2021
entrez:
21
12
2019
Statut:
ppublish
Résumé
This study aimed to assess the safety and efficacy of sofosbuvir (SOF)-based regimens in patients with moderate to severe renal impairment; a subject which has been questioned by many investigators with conflicting results. This is a real-life multicentre retrospective cohort study on 4944 chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) (eGFR <60 mL/min/1.73 m Week 12 virological response rates were 97.5%, 96.7%, 85.7% and 80% in the total cohort, patients with eGFR <30 mL/min/1.73 m Sofosbuvir-based regimens are effective and safe for treating patients with chronic HCV and moderate to severe CKD, and in those with associated hepatic decompensation.
Sections du résumé
BACKGROUND AND AIMS
This study aimed to assess the safety and efficacy of sofosbuvir (SOF)-based regimens in patients with moderate to severe renal impairment; a subject which has been questioned by many investigators with conflicting results.
METHODS
This is a real-life multicentre retrospective cohort study on 4944 chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) (eGFR <60 mL/min/1.73 m
RESULTS
Week 12 virological response rates were 97.5%, 96.7%, 85.7% and 80% in the total cohort, patients with eGFR <30 mL/min/1.73 m
CONCLUSION
Sofosbuvir-based regimens are effective and safe for treating patients with chronic HCV and moderate to severe CKD, and in those with associated hepatic decompensation.
Substances chimiques
Antiviral Agents
0
Ribavirin
49717AWG6K
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
797-805Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
World health organization (WHO). Hepatitis C fact sheets. 2018. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed March 2019 .
Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci. 2015;60:3801-3813.
Bianco A, Bova F, Nobile CG, Pileggi C, Pavia M. Healthcare workers and prevention of hepatitis C virus transmission: exploring knowledge, attitudes and evidence-based practices in hemodialysis units in Italy. BMC Infect Dis. 2013;13:76.
Harfouche M, Chemaitelly H, Mahmud S, et al. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. Epidemiol Infect. 2017;145:3243-3263.
Shimokura G, Chai F, Weber DJ, et al. Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol. 2011;32(5):415-424.
Bagnis IC, Cacoub P. Hepatitis C therapy in renal patients: who, how, when? Infect Dis Ther. 2016;5:313-327.
Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12:287-297.
Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37:534-541.
Cholongitasa E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 2014;27:331-337.
EASL recommendations on treatment of hepatitis-C 2016. J Hepatol. 2017;66:153-194.
Sovaldi US Prescribing Information, December 2013. http://www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/sovaldi/sovaldi_pi.pdf. Accessed April 2019.
Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal function. Liver Int. 2016;36:807-816.
Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun. 2017;1:248-255.
Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71(4):660-665.
Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40-47.
Bhamidimarri KR, Martin P. Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. J Hepatol. 2016;65:7-10.
Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2017;32:2065-2071.
Agarwal SK, Bagchi S, Yadav RK. Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen. Kidney Int Rep. 2017;2:831-835.
Gupta A, Arora P, Jain P. Sofosbuvir based regimen in management of hepatitis C for patients with end stage renal disease hemodialysis: a single center experience from India. J Clin Exp Hepatol. 2018;8:116-120.
Choudhary NS, Kumar A, Bodh V, et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroentero. 2017;36:113-116.
Perumpail RB, Wong RJ, Ha LD, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17:275-278.
Gevers TJG, Burger D, Schipper-Reintjes E, Kooistra MP, Richter C. Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients. Neth J Med. 2016;74:225-227.
Beinhardt S, Al Zoairy R, Ferenci P, et al. A.DAA-based antiviral treatment of patients with chronic hepatitis C in the pre-and post-kidney transplantation setting. Transpl Int. 2016;29:999-1007.
Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh I, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int. 2016;36:802-806.
Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int. 2016;36:798-801.
Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis. 2015;47:924-929.
Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194.
National kidney foundation. CKD-EPI CREATININE EQUATION, 2009. https://www.kidney.org/content/ckd-epi-creatinine-equation-2009, Accessed in March 2019.
Sterling RK1, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350.
Kidney Disease Improving outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Statistical analysis. Kidney Int Suppl (2011). 2017;7:1-59.
El-Fishawy H, Saadi G, Hassaballa M, et al. Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations-An Egyptian perspective. J Adv Res. 2016;7:391-402.
Fox RK, Spach DH, Kim HN.Treatment of HCV in Persons with Renal Impairment. Hepatitis C online. Section 6. Treatment of Key Populations and Unique Situations. Topic 3. Treatment of HCV in Persons with Renal Impairment Last Updated: July 16th, 2018. www.hepatitisc.uw.edu/go/key-populations-situations/treatment-renal-impairment. Accessed March 2019.
Shin HP, Park JA, Burman B, Kozarek RA, Siddique A. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Clin Mol Hepatol. 2017;23:316-322.
Hassany M, Elsharkawy A. HCV treatment failure in the Era of DAAs. INTECH open science. 2017;Chapter 6:117-129.
Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292.
Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-SamrA AB. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018;48:35-43.
Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.
Singh A, Kumari S, Kumar P, De A, Singh V. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency. J Viral Hepat. 2018;25:1501-1506.
EASL Clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-446.